• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Action Mechanism
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global Pulmonary Arterial Hypertension Drugs Market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global Pulmonary Arterial Hypertension Drugs Market 2017 – 2021 ($ million)
o 4.2 Route of Administration Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
o 4.3 Action Mechanism Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Action Mechanism Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Route of Administration – Market share 2022-2027 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Oral – Market size and forecast 2022-2027
o Exhibit 34: Chart on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Oral – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Oral – Year-over-year growth 2022-2027 (%)
o 6.4 Injectable – Market size and forecast 2022-2027
o Exhibit 38: Chart on Injectable – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Injectable – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Injectable – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Injectable – Year-over-year growth 2022-2027 (%)
o 6.5 Inhalation – Market size and forecast 2022-2027
o Exhibit 42: Chart on Inhalation – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Inhalation – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Inhalation – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Inhalation – Year-over-year growth 2022-2027 (%)
o 6.6 Market opportunity by Route of Administration
o Exhibit 46: Market opportunity by Route of Administration ($ million)
o Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Action Mechanism
o 7.1 Market segments
o Exhibit 48: Chart on Action Mechanism – Market share 2022-2027 (%)
o Exhibit 49: Data Table on Action Mechanism – Market share 2022-2027 (%)
o 7.2 Comparison by Action Mechanism
o Exhibit 50: Chart on Comparison by Action Mechanism
o Exhibit 51: Data Table on Comparison by Action Mechanism
o 7.3 Prostacyclin analogs – Market size and forecast 2022-2027
o Exhibit 52: Chart on Prostacyclin analogs – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Prostacyclin analogs – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Prostacyclin analogs – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Prostacyclin analogs – Year-over-year growth 2022-2027 (%)
o 7.4 Endothelin receptor antagonists (ERAs) – Market size and forecast 2022-2027
o Exhibit 56: Chart on Endothelin receptor antagonists (ERAs) – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Endothelin receptor antagonists (ERAs) – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Endothelin receptor antagonists (ERAs) – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Endothelin receptor antagonists (ERAs) – Year-over-year growth 2022-2027 (%)
o 7.5 Phosphodiesterase (PDE) inhibitors – Market size and forecast 2022-2027
o Exhibit 60: Chart on Phosphodiesterase (PDE) inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Phosphodiesterase (PDE) inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Phosphodiesterase (PDE) inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Phosphodiesterase (PDE) inhibitors – Year-over-year growth 2022-2027 (%)
o 7.6 Soluble guanylate cyclase stimulators (SGCSs) – Market size and forecast 2022-2027
o Exhibit 64: Chart on Soluble guanylate cyclase stimulators (SGCSs) – Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Data Table on Soluble guanylate cyclase stimulators (SGCSs) – Market size and forecast 2022-2027 ($ million)
o Exhibit 66: Chart on Soluble guanylate cyclase stimulators (SGCSs) – Year-over-year growth 2022-2027 (%)
o Exhibit 67: Data Table on Soluble guanylate cyclase stimulators (SGCSs) – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Action Mechanism
o Exhibit 68: Market opportunity by Action Mechanism ($ million)
o Exhibit 69: Data Table on Market opportunity by Action Mechanism ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 71: Chart on Market share by geography 2022-2027 (%)
o Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 73: Chart on Geographic comparison
o Exhibit 74: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 75: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 79: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 83: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 87: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 91: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 UK – Market size and forecast 2022-2027
o Exhibit 95: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 99: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 Canada – Market size and forecast 2022-2027
o Exhibit 103: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.11 Japan – Market size and forecast 2022-2027
o Exhibit 107: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 108: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 109: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 110: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 111: Market opportunity by geography ($ million)
o Exhibit 112: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 113: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 115: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 116: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 117: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 118: Matrix on vendor position and classification
o 12.3 Aerami Therapeutics Holdings Inc.
o Exhibit 119: Aerami Therapeutics Holdings Inc. – Overview
o Exhibit 120: Aerami Therapeutics Holdings Inc. – Product / Service
o Exhibit 121: Aerami Therapeutics Holdings Inc. – Key offerings
o 12.4 Asklepion Pharmaceuticals LLC
o Exhibit 122: Asklepion Pharmaceuticals LLC – Overview
o Exhibit 123: Asklepion Pharmaceuticals LLC – Product / Service
o Exhibit 124: Asklepion Pharmaceuticals LLC – Key offerings
o 12.5 AstraZeneca Plc
o Exhibit 125: AstraZeneca Plc – Overview
o Exhibit 126: AstraZeneca Plc – Product / Service
o Exhibit 127: AstraZeneca Plc – Key news
o Exhibit 128: AstraZeneca Plc – Key offerings
o 12.6 Bayer AG
o Exhibit 129: Bayer AG – Overview
o Exhibit 130: Bayer AG – Business segments
o Exhibit 131: Bayer AG – Key news
o Exhibit 132: Bayer AG – Key offerings
o Exhibit 133: Bayer AG – Segment focus
o 12.7 Daiichi Sankyo Co. Ltd.
o Exhibit 134: Daiichi Sankyo Co. Ltd. – Overview
o Exhibit 135: Daiichi Sankyo Co. Ltd. – Business segments
o Exhibit 136: Daiichi Sankyo Co. Ltd. – Key news
o Exhibit 137: Daiichi Sankyo Co. Ltd. – Key offerings
o Exhibit 138: Daiichi Sankyo Co. Ltd. – Segment focus
o 12.8 Eiger BioPharmaceuticals Inc.
o Exhibit 139: Eiger BioPharmaceuticals Inc. – Overview
o Exhibit 140: Eiger BioPharmaceuticals Inc. – Product / Service
o Exhibit 141: Eiger BioPharmaceuticals Inc. – Key offerings
o 12.9 Gilead Sciences Inc.
o Exhibit 142: Gilead Sciences Inc. – Overview
o Exhibit 143: Gilead Sciences Inc. – Product / Service
o Exhibit 144: Gilead Sciences Inc. – Key news
o Exhibit 145: Gilead Sciences Inc. – Key offerings
o 12.10 GlaxoSmithKline Plc
o Exhibit 146: GlaxoSmithKline Plc – Overview
o Exhibit 147: GlaxoSmithKline Plc – Business segments
o Exhibit 148: GlaxoSmithKline Plc – Key news
o Exhibit 149: GlaxoSmithKline Plc – Key offerings
o Exhibit 150: GlaxoSmithKline Plc – Segment focus
o 12.11 Johnson and Johnson Services Inc.
o Exhibit 151: Johnson and Johnson Services Inc. – Overview
o Exhibit 152: Johnson and Johnson Services Inc. – Business segments
o Exhibit 153: Johnson and Johnson Services Inc. – Key news
o Exhibit 154: Johnson and Johnson Services Inc. – Key offerings
o Exhibit 155: Johnson and Johnson Services Inc. – Segment focus
o 12.12 Lupin Ltd.
o Exhibit 156: Lupin Ltd. – Overview
o Exhibit 157: Lupin Ltd. – Product / Service
o Exhibit 158: Lupin Ltd. – Key news
o Exhibit 159: Lupin Ltd. – Key offerings
o 12.13 Merck and Co. Inc.
o Exhibit 160: Merck and Co. Inc. – Overview
o Exhibit 161: Merck and Co. Inc. – Business segments
o Exhibit 162: Merck and Co. Inc. – Key news
o Exhibit 163: Merck and Co. Inc. – Key offerings
o Exhibit 164: Merck and Co. Inc. – Segment focus
o 12.14 Novartis AG
o Exhibit 165: Novartis AG – Overview
o Exhibit 166: Novartis AG – Business segments
o Exhibit 167: Novartis AG – Key offerings
o Exhibit 168: Novartis AG – Segment focus
o 12.15 Pfizer Inc.
o Exhibit 169: Pfizer Inc. – Overview
o Exhibit 170: Pfizer Inc. – Product / Service
o Exhibit 171: Pfizer Inc. – Key news
o Exhibit 172: Pfizer Inc. – Key offerings
o 12.16 Teva Pharmaceutical Industries Ltd.
o Exhibit 173: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 174: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 175: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 176: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 177: Teva Pharmaceutical Industries Ltd. – Segment focus
o 12.17 United Therapeutics Corp.
o Exhibit 178: United Therapeutics Corp. – Overview
o Exhibit 179: United Therapeutics Corp. – Product / Service
o Exhibit 180: United Therapeutics Corp. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 181: Inclusions checklist
o Exhibit 182: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 183: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 184: Research methodology
o Exhibit 185: Validation techniques employed for market sizing
o Exhibit 186: Information sources
o 13.5 List of abbreviations
o Exhibit 187: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary – Chart on Market Segmentation by Action Mechanism
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global Pulmonary Arterial Hypertension Drugs Market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Action Mechanism Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Route of Administration – Market share 2022-2027 (%)
Exhibits31: Data Table on Route of Administration – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oral – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oral – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Injectable – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Injectable – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Injectable – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Injectable – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Inhalation – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Inhalation – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Inhalation – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Inhalation – Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by Route of Administration ($ million)
Exhibits47: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits48: Chart on Action Mechanism – Market share 2022-2027 (%)
Exhibits49: Data Table on Action Mechanism – Market share 2022-2027 (%)
Exhibits50: Chart on Comparison by Action Mechanism
Exhibits51: Data Table on Comparison by Action Mechanism
Exhibits52: Chart on Prostacyclin analogs – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Prostacyclin analogs – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Prostacyclin analogs – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Prostacyclin analogs – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Endothelin receptor antagonists (ERAs) – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Endothelin receptor antagonists (ERAs) – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Endothelin receptor antagonists (ERAs) – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Endothelin receptor antagonists (ERAs) – Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Phosphodiesterase (PDE) inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Phosphodiesterase (PDE) inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Phosphodiesterase (PDE) inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Phosphodiesterase (PDE) inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits64: Chart on Soluble guanylate cyclase stimulators (SGCSs) – Market size and forecast 2022-2027 ($ million)
Exhibits65: Data Table on Soluble guanylate cyclase stimulators (SGCSs) – Market size and forecast 2022-2027 ($ million)
Exhibits66: Chart on Soluble guanylate cyclase stimulators (SGCSs) – Year-over-year growth 2022-2027 (%)
Exhibits67: Data Table on Soluble guanylate cyclase stimulators (SGCSs) – Year-over-year growth 2022-2027 (%)
Exhibits68: Market opportunity by Action Mechanism ($ million)
Exhibits69: Data Table on Market opportunity by Action Mechanism ($ million)
Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits71: Chart on Market share by geography 2022-2027 (%)
Exhibits72: Data Table on Market share by geography 2022-2027 (%)
Exhibits73: Chart on Geographic comparison
Exhibits74: Data Table on Geographic comparison
Exhibits75: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits107: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits108: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits109: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits110: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits111: Market opportunity by geography ($ million)
Exhibits112: Data Tables on Market opportunity by geography ($ million)
Exhibits113: Impact of drivers and challenges in 2022 and 2027
Exhibits114: Overview on Criticality of inputs and Factors of differentiation
Exhibits115: Overview on factors of disruption
Exhibits116: Impact of key risks on business
Exhibits117: Vendors covered
Exhibits118: Matrix on vendor position and classification
Exhibits119: Aerami Therapeutics Holdings Inc. – Overview
Exhibits120: Aerami Therapeutics Holdings Inc. – Product / Service
Exhibits121: Aerami Therapeutics Holdings Inc. – Key offerings
Exhibits122: Asklepion Pharmaceuticals LLC – Overview
Exhibits123: Asklepion Pharmaceuticals LLC – Product / Service
Exhibits124: Asklepion Pharmaceuticals LLC – Key offerings
Exhibits125: AstraZeneca Plc – Overview
Exhibits126: AstraZeneca Plc – Product / Service
Exhibits127: AstraZeneca Plc – Key news
Exhibits128: AstraZeneca Plc – Key offerings
Exhibits129: Bayer AG – Overview
Exhibits130: Bayer AG – Business segments
Exhibits131: Bayer AG – Key news
Exhibits132: Bayer AG – Key offerings
Exhibits133: Bayer AG – Segment focus
Exhibits134: Daiichi Sankyo Co. Ltd. – Overview
Exhibits135: Daiichi Sankyo Co. Ltd. – Business segments
Exhibits136: Daiichi Sankyo Co. Ltd. – Key news
Exhibits137: Daiichi Sankyo Co. Ltd. – Key offerings
Exhibits138: Daiichi Sankyo Co. Ltd. – Segment focus
Exhibits139: Eiger BioPharmaceuticals Inc. – Overview
Exhibits140: Eiger BioPharmaceuticals Inc. – Product / Service
Exhibits141: Eiger BioPharmaceuticals Inc. – Key offerings
Exhibits142: Gilead Sciences Inc. – Overview
Exhibits143: Gilead Sciences Inc. – Product / Service
Exhibits144: Gilead Sciences Inc. – Key news
Exhibits145: Gilead Sciences Inc. – Key offerings
Exhibits146: GlaxoSmithKline Plc – Overview
Exhibits147: GlaxoSmithKline Plc – Business segments
Exhibits148: GlaxoSmithKline Plc – Key news
Exhibits149: GlaxoSmithKline Plc – Key offerings
Exhibits150: GlaxoSmithKline Plc – Segment focus
Exhibits151: Johnson and Johnson Services Inc. – Overview
Exhibits152: Johnson and Johnson Services Inc. – Business segments
Exhibits153: Johnson and Johnson Services Inc. – Key news
Exhibits154: Johnson and Johnson Services Inc. – Key offerings
Exhibits155: Johnson and Johnson Services Inc. – Segment focus
Exhibits156: Lupin Ltd. – Overview
Exhibits157: Lupin Ltd. – Product / Service
Exhibits158: Lupin Ltd. – Key news
Exhibits159: Lupin Ltd. – Key offerings
Exhibits160: Merck and Co. Inc. – Overview
Exhibits161: Merck and Co. Inc. – Business segments
Exhibits162: Merck and Co. Inc. – Key news
Exhibits163: Merck and Co. Inc. – Key offerings
Exhibits164: Merck and Co. Inc. – Segment focus
Exhibits165: Novartis AG – Overview
Exhibits166: Novartis AG – Business segments
Exhibits167: Novartis AG – Key offerings
Exhibits168: Novartis AG – Segment focus
Exhibits169: Pfizer Inc. – Overview
Exhibits170: Pfizer Inc. – Product / Service
Exhibits171: Pfizer Inc. – Key news
Exhibits172: Pfizer Inc. – Key offerings
Exhibits173: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits174: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits175: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits176: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits177: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits178: United Therapeutics Corp. – Overview
Exhibits179: United Therapeutics Corp. – Product / Service
Exhibits180: United Therapeutics Corp. – Key offerings
Exhibits181: Inclusions checklist
Exhibits182: Exclusions checklist
Exhibits183: Currency conversion rates for US$
Exhibits184: Research methodology
Exhibits185: Validation techniques employed for market sizing
Exhibits186: Information sources
Exhibits187: List of abbreviations